Insider · CIK 0001927032
Lynn Stockwell
Files at DMAA (Drugs Made In America Acquisition Corp.), DMII (Drugs Made In America Acquisition II Corp.). First filing -, latest -.
Lynn Stockwell files SEC Form 4 as CEO, director, 10% owner and chair at DMAA (Drugs Made In America Acquisition Corp.), and also at DMII (Drugs Made In America Acquisition II Corp.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Lynn Stockwell has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 26, 2025 | DMII Drugs Made In America Acquisition II Corp. | POpen-market purchase Ordinary sharesindirect: See Footnote | +700,000 | - | - | 15,075,000 | Oct 1, 2025 |
| Sep 26, 2025 | DMII Drugs Made In America Acquisition II Corp. | JOther Ordinary sharesindirect: See Footnote | -400,000 | - | - | 14,675,000 | Oct 1, 2025 |
| Sep 26, 2025 | DMII Drugs Made In America Acquisition II Corp. | SOpen-market sale Ordinary sharesindirect: See Footnote | -7,966,667 | - | - | 6,708,333 | Oct 1, 2025 |
| Sep 26, 2025 | DMII Drugs Made In America Acquisition II Corp. | POpen-market purchase Rights to receive ordinary sharesderivativeindirect: See Footnote | +700,000 | - | - | 700,000 | Oct 1, 2025 |
| Feb 18, 2025 | DMAA Drugs Made In America Acquisition Corp. | POpen-market purchase Ordinary sharesindirect: See Footnotes | +30,000 | - | - | 4,188,780 | Feb 18, 2025 |
| Feb 18, 2025 | DMAA Drugs Made In America Acquisition Corp. | POpen-market purchase Rights to receive ordinary sharesderivativeindirect: See Footnotes | +30,000 | - | - | 430,000 | Feb 18, 2025 |
| Jan 29, 2025 | DMAA Drugs Made In America Acquisition Corp. | POpen-market purchase Ordinary sharesindirect: See footnote | +400,000 | - | - | 10,257 | Feb 4, 2025 |
| Jan 29, 2025 | DMAA Drugs Made In America Acquisition Corp. | JOther Ordinary sharesindirect: See footnote | -400,000 | - | - | 9,857,143 | Feb 4, 2025 |
| Jan 29, 2025 | DMAA Drugs Made In America Acquisition Corp. | SOpen-market sale Ordinary sharesindirect: See footnote | -5,698,363 | - | - | 4,158,780 | Feb 4, 2025 |
| Jan 29, 2025 | DMAA Drugs Made In America Acquisition Corp. | POpen-market purchase Rights to receive ordinary sharesderivativeindirect: See footnote | +400,000 | - | - | 400,000 | Feb 4, 2025 |
Questions about Lynn Stockwell
Answered from the filings on this page, as of the latest one.
Is Lynn Stockwell buying or selling?
Lynn Stockwell has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Lynn Stockwell's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Lynn Stockwell has 0.
Where does Lynn Stockwell file Form 4?
Lynn Stockwell has filed Form 4 at DMAA (Drugs Made In America Acquisition Corp.) as CEO and Exe. Chair of Board; DMII (Drugs Made In America Acquisition II Corp.) as CEO and Exe. Chair of Board. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.